Motorized Outer Tubing Cutter for UltiPace Leads
ABBOTT MEDICAL · Decision date Oct 9, 2026
What did the FDA decide?
FDA recorded a 30-Day Notice decision, OK30, dated 2026-10-09 for P960013/S135, submitted by Abbott Medical. The supplement covers a process change attributed to a manufacturer, sterilizer, packager or supplier, and its stated scope is to implement automated cutting equipment for outer tubing used in UltiPace leads. The notice concerns the tubing-cutting step rather than a new lead design.
The underlying device category is drug eluting permanent right ventricular or right atrial pacemaker electrodes, classified under product code NVN in the Cardiovascular specialty. Because this is a PMA supplement, the record addresses the described manufacturing change only; it is not an approval of the whole system, and no clinical, efficacy or patient-selection conclusions follow from it. The source lists no supporting documents, so the technical content of the change and any conditions of the decision remain unknown.
FDA approval order statement
to implement automated cutting equipment for outer tubing used in UltiPace leads
- Regulatory pathway
- PMA supplement
- Supplement type
- 30-Day Notice
- Clinical specialty
- Cardiovascular
- Decision date
- Oct 9, 2026
- FDA change category
- Process Change - Manufacturer/Sterilizer/Packager/Supplier
FDA source record · MedtechLedger’s explanation describes the recorded change.
Regulatory record facts
- Identifier
- P960013/S135
- Regulatory pathway
- PMA supplement
- Applicant
- ABBOTT MEDICAL
- Product code
- NVN
- Decision code
- OK30
- Decision date
- Oct 9, 2026
- Source update
- Nov 9, 2026
- Original record
- Open FDA source record
About this medical device
FDA device category: Drug eluting permanent right ventricular (RV) or right atrial (RA) pacemaker electrodes.
- Applicant
- Abbott Medical
- Product code
- NVN
- FDA device class
- 3
For the original device and its historical approval scope, see PMA P960013. Subsequent supplements may change the device or its indications.
FDA decision timeline
P960013 · Original PMA
TENDRIL DX MODEL 1388T & 1388K ENDOCARDIAL PACING LEADS
P960013/S135 received
Application receipt date recorded by FDA.
P960013/S135 · FDA decision
30-Day Notice
Timeline entries are records held by MedtechLedger for P960013. View FDA’s full supplement list.
Related devices and submissions
Same PMA: P960013
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
| ABBOTT MEDICAL | PMA approval | Jun 20, 1997 | FDA |
Explore the linked device profile
Other records with product code NVN
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
MEDTRONIC SELECTSECURE LEAD MODEL 3830P030036/S162 | Medtronic Cardiac Rhythm Disease Management | PMA supplement | Oct 16, 2026 | FDA |
| Medtronic Cardiac Rhythm Disease Management | PMA approval | Aug 3, 2005 | FDA |
A shared product code identifies a classification relationship; it does not establish clinical equivalence.
Regulatory context
A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.
Read our guide to FDA clearance and approval · FDA’s explanation of this pathway
Manufacturer intelligence
Abbott Medical
- Headquarters
- Not reported
- Brand website
- abbott.com
- FDA applicant address
- 15900 Valley View Ct., Sylmar, CA, 91335
Sources and methodology
- Original FDA record: P960013/S135
- openFDA source data · Source release Nov 9, 2026 · Retrieved Nov 19, 2026
FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.
How we use FDA records

